This could happen, but why would Novartis want this? who has a network of doctors passionate about stem cell therapy? If SI and the current team walked, due to a hostile TO, this stem cell space won't be the same. Even if you could employ them, there could be less motivation and passion to drive the product into the market. This market is NOT ready for a hostile TO IMO, at least you can't do it without risk of losing all your talents or motivated clinicians.
Support us MSB now, and with the network of clinicians is the best chance to get MSCs approved. Once a single product is approved, then come TO MSB, yes it will be more expensive but much less risky.
Side note, the longer we wait for the ARDS results, the more likely the result will be positive with secondary endpoints analysis.
Deadline for Novartis, page-195
-
- There are more pages in this discussion • 235 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |